News Column

NanoString Strengthens Capabilities of Its nCounter Elements General Purpose Reagents

August 1, 2014

NanoString Technologies said that it has expanded the capabilities of its nCounter Elements General Purpose Reagents (GPRs) with the addition of a universal junction probe design that offers specific detection and analysis of known fusion genes.

In its release, the Company said that it reported the availability of the new design capability to early access customers at the 2014 American Association for Clinical Chemistry annual meeting in Chicago.

Brad Gray, President and Chief Executive Officer of NanoString Technologies said: "With this new technology, NanoString can now design probes for virtually any fusion junction. As a result, our customers can design and develop full custom sets of probes for their fusion junction sequences of interest. We are proud to partner with the Wyss Institute at Harvard University to bring this latest advance to the market and further bolster our growing portfolio of validated tools for cancer research and personalized medicine."

Fusions genes are hybrid genes formed from two previously separate genes. NanoString said that an increasing number of these genes are being recognized as important diagnostic and prognostic indicators in human cancers and diseases. nCounter Elements GPRs enable clinical laboratories to independently develop multiplexed genomic assays and then translate those assays into clinical diagnostics as Laboratory Developed Tests (LDTs).

NanoString said that its new junction probe design was created based on technology developed by Peng Yin Ph.D., core faculty member at the Wyss Institute for Biologically Inspired Engineering at Harvard University and assistant professor at the Department of Systems Biology at Harvard Medical School, and David Zhang, former Postdoctoral Fellow at the Wyss Institute and Ted Law Jr. Assistant Professor of Bioengineering at Rice University.

"These multiplexed fusion assays offer an alternative to singleplex FISH, qPCR, and IHC assays that maximizes the information generated from scarce samples and enables the addition of new fusions without an increase in sample input amount or labor," said Dr. Mao Mao, Senior Vice President of Translational Bioscience and Diagnostics at Wuxi AppTec.

More Information and Complete Details:

((Comments on this story may be sent to

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Health & Beauty Close - Up

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters